BridgeBio Pharma: Peers

The FY2025 (Dec) proxy of BridgeBio Pharma names 21 peer companies for pay. Among BridgeBio Pharma and these peers, CEO pay was 6th highest of 9 and total shareholder return was 8th highest of 9.

6th highest of 9in BridgeBio Pharma and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

8th highest of 9in BridgeBio Pharma and its pay peers, FY2025 (Dec) by total shareholder return:

$17$524

Pay peer group, FY2025 (Dec) proxy

Exelixis
Incyte
PTC Therapeutics
Halozyme Therapeutics
Madrigal Pharmaceuticals
Ionis Pharmaceuticals
Ultragenyx Pharmaceutical
Neurocrine Biosciences
Acadia Pharmaceuticals Inc.Not disclosedNot disclosed
Amicus Therapeutics, Inc.Not disclosedNot disclosed
Apellis Pharmaceuticals, Inc.Not disclosedNot disclosed
Arrowhead Pharmaceuticals, Inc.Not disclosedNot disclosed
BioMarin Pharmaceuticals Inc.Not disclosedNot disclosed
Biohaven Ltd.Not disclosedNot disclosed
Blueprint Medicines CorporationNot disclosedNot disclosed
Cytokinetics, IncorporatedNot disclosedNot disclosed
Iovance Biotherapeutics, IncNot disclosedNot disclosed
Jazz Pharmaceuticals Public Limited CompanyNot disclosedNot disclosed
Roivant SciencesNot disclosedNot disclosed
Sarepta Therapeutics, Inc.Not disclosedNot disclosed
SpringWorks Therapeutics, Inc.Not disclosedNot disclosed
21 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.